References
- Cherny NI, Portenoy RK. The management of cancer pain. CA Cancer J Clin 1994;44:263–303. doi:10.3322/canjclin.44.5.263
- Paice JA. Cancer pain management and the opioid crisis in America: how to preserve hard-earned gains in improving the quality of cancer pain management. Cancer 2018;124:2491–7. doi:10.1002/cncr.31303
- Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era [Internet]. CA Cancer J Clin 2018;68(3):182–196. doi:10.3322/caac.21453
- Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol [Internet] 2023 [cited 2023 Feb 27];41(4):914–930. https://pubmed.ncbi.nlm.nih.gov/36469839/.
- Swarm RA, Paice JA, Anghelescu DL, et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw [Internet] 2019 [cited 2023 Feb 27];17(8):977–1007. https://pubmed.ncbi.nlm.nih.gov/31390582/.
- Burma NE, Kwok CH, Trang T. Therapies and mechanisms of opioid withdrawal. Pain Manag [Internet] 2017 [cited 2022 Nov 22];7(6):455–459. https://pubmed.ncbi.nlm.nih.gov/29125396/.
- Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev [Internet] 2009;2(2). https://pubmed.ncbi.nlm.nih.gov/19588330/.
- Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol [Internet] 2001 [cited 2022 Nov 22];19(9):2542–2554. https://pubmed.ncbi.nlm.nih.gov/11331334/.
- O’Brien CB, Locklear CE, Glovak ZT, et al. Opioids cause dissociated states of consciousness in C57BL/6J mice. J Neurophysiol [Internet] 2021 [cited 2022 Nov 22];126(4):1265–1275. https://pubmed.ncbi.nlm.nih.gov/34469699/.
- Montandon G, Horner RL. Electrocortical changes associating sedation and respiratory depression by the opioid analgesic fentanyl. Sci Rep [Internet] 2019 [cited 2022 Nov 22];9(1). https://pubmed.ncbi.nlm.nih.gov/31575947/.
- Boland J, Boland E, Brooks D. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone. Clin Med 2013;13:149–51. doi:10.7861/clinmedicine.13-2-149
- Desai PH, Taylor O, Shah KJ, et al. Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Mental Health Clinician 2021;11:225–30. doi:10.9740/mhc.2021.07.225
- Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Arch Toxicol [Internet] 2021 [cited 2022 Oct 31];95(8):2627–2642. https://pubmed.ncbi.nlm.nih.gov/33974096/.
- Ramirez JM, Burgraff NJ, Wei AD, et al. Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding. J Neurophysiol [Internet] 2021 [cited 2022 Nov 21];125(5):1899–1919. https://pubmed.ncbi.nlm.nih.gov/33826874/.
- Pattinson KT. Opioids and the control of respiration. Br J Anaesth [Internet] 2008 [cited 2022 Nov 21];100(6):747–758. https://pubmed.ncbi.nlm.nih.gov/18456641/.
- Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. Anaesth Intensive Care [Internet] 2022 [cited 2022 Nov 21];50(1-2):52–67. https://pubmed.ncbi.nlm.nih.gov/35189729/.
- Teichtahl H, Wang D, Cunnington D, et al. Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. Chest [Internet] 2005 [cited 2022 Nov 21];128(3):1339–1347. https://pubmed.ncbi.nlm.nih.gov/16162727/.
- Wang D, Yee BJ, Grunstein RR, et al. Chronic opioid use and central sleep apnea, where are we now and where to go? A state of the art review. Anesth Analg [Internet] 2021 [cited 2022 Nov 21];132(5):1244–1253. https://pubmed.ncbi.nlm.nih.gov/33857966/.
- Ellingsrud C, Agewall S. Morphine in the treatment of acute pulmonary oedema–why? Int J Cardiol [Internet] 2016 [cited 2022 Nov 22];202:870–873. https://pubmed.ncbi.nlm.nih.gov/26476045/.
- Faull OK, Jenkinson M, Clare S, et al. Functional subdivision of the human periaqueductal grey in respiratory control using 7 tesla fMRI. Neuroimage [Internet] 2015 [cited 2022 Nov 22];113:356–364. https://pubmed.ncbi.nlm.nih.gov/25703831/.
- Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther [Internet] 1994 [cited 2022 Dec 22];55(5):569–580. https://pubmed.ncbi.nlm.nih.gov/8181201/.
- Geary WA, Wooten GF. Regional saturation studies of [3H]naloxone binding in the naive, dependent and withdrawal states. Brain Res [Internet] 1985 [cited 2022 Nov 28];360(1-2):214–223. https://pubmed.ncbi.nlm.nih.gov/4075170/.
- Sawynok J, Pinsky C, LaBella FS. On the specificity of naloxone as an opiate antagonist. Life Sci [Internet] 1979 [cited 2022 Nov 28];25(19):1621–1631. https://pubmed.ncbi.nlm.nih.gov/229377/.
- Paul G. Opioid Overdose and Withdrawal. In: Pain Management and Palliative Care. New York, NY: Springer; 2015. p.45–48. https://doi.org/10.1007/978-1-4939-2462-2_7.
- Kanof PD, Handelsman L, Aronson MJ, et al. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther 1992;260:355–63.
- Moe J, Godwin J, Purssell R, et al. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. Canad J Emerg Med 2020;22:178–86. doi:10.1017/cem.2019.471
- Lynn RR, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Therap Adv Drug Safety 2018;9:63.
- Wong G, Greenhalgh T, Westhorp G, et al. RAMESES publication standards: realist syntheses. BMC med [Internet] 2013 [cited 2023 Apr 10];11(21). https://pubmed.ncbi.nlm.nih.gov/23360677/.
- O’Brien J, Dingle M. A dual realist review: compression for leg swelling at the end of life has potential quality of life benefit. J Adv Nurs 2022;78:4003–18. doi:10.1111/jan.15458
- Dada S, Dalkin S, Gilmore B, et al. Applying and reporting relevance, richness and rigour in realist evidence appraisals: advancing key concepts in realist reviews. Res Synth Methods [Internet] 2023;14(3):504–514. https://pubmed.ncbi.nlm.nih.gov/36872619/.
- McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231–56. doi:10.1016/S1526-5900(03)00556-X
- Manfredi PL, Ribeiro S, Chandler SW, et al. Inappropriate use of naloxone in cancer patients with pain. J Pain Symptom Manage [Internet] 1996 [cited 2022 Oct 27];11(2):131–134. https://pubmed.ncbi.nlm.nih.gov/8907145/.
- Howlett C, Gonzalez R, Yerram P, et al. Use of naloxone for reversal of life-threatening opioid toxicity in cancer-related pain. J Oncol Pharm Pract [Internet] 2016 [cited 2022 Oct 27];22:114–120. https://pubmed.ncbi.nlm.nih.gov/25227231/.
- Facey C, Brooks D, Boland JW. Assessment of the appropriateness of naloxone administration to patients receiving long-term opioid therapy. Hosp Pract [Internet] 2016 [cited 2022 Oct 31];44:86–91. https://pubmed.ncbi.nlm.nih.gov/26837434/.
- Gordon DB, Pellino TA. Incidence and characteristics of naloxone use in postoperative pain management: a critical examination of naloxone use as a potential quality measure. Pain Manag Nurs [Internet] 2005 [cited 2022 Oct 31];6(1):30–36. https://pubmed.ncbi.nlm.nih.gov/15917742/.
- Lynch M. Pain as the fifth vital sign. J Intraven Nurs [Internet] 2001 [cited 2022 Oct 31];24(2):85–94. https://pubmed.ncbi.nlm.nih.gov/11836838/.
- Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology [Internet] 2015 [cited 2022 Oct 31];122:659–665. https://pubmed.ncbi.nlm.nih.gov/25536092/.
- Connors NJ, Nelson LS. The evolution of recommended naloxone dosing for opioid overdose by medical specialty. J Med Toxicol 2016;12:276.
- Meadows J, McGee K, Goldberg J, et al. Creating simple solutions for safe naloxone use. J Clin Oncol [Internet] 2017; 35:e18185–e18185. 10.1200/JCO.2017.35.15_suppl.e18185.
- Osterwalder JJ. Naloxone–for intoxications with intravenous heroin and heroin mixtures–harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol [Internet] 1996 [cited 2022 Oct 31];34(4):409–416. https://pubmed.ncbi.nlm.nih.gov/8699555/.
- Farkas A, Lynch MJ, Westover R, et al. Pulmonary complications of opioid overdose treated with naloxone. Ann Emerg Med 2020;75:39–48. doi:10.1016/j.annemergmed.2019.04.006
- Jiwa N, Sheth H, Silverman R. Naloxone-induced non-cardiogenic pulmonary edema: a case report. Drug Safety - Case Rep 2018;5:1–4. doi:10.1007/s40800-018-0088-x
- Patti R, Ponnusamy V, Somal N, et al. Naloxone-Induced noncardiogenic pulmonary edema. Am J Ther 2020;27:e672. doi:10.1097/MJT.0000000000001037
- Al-Azzawi M, Alshami A, Douedi S, et al. Naloxone-induced acute pulmonary edema is dose-dependent: a case series. Am J Case Rep 2021;22:e929412–1. doi:10.12659/AJCR.929412
- Kummer RL, Kempainen RR, Olives TD, et al. Naloxone-associated pulmonary edema following recreational opioid overdose. Am J Emerg Med [Internet] 2022 [cited 2022 Oct 31];53:41–43. https://pubmed.ncbi.nlm.nih.gov/34973491/.
- Olofsen E, Algera MH, Moss L, et al. Modeling buprenorphine reduction of fentanyl-induced respiratory depression. JCI insight [Internet] 2022 [cited 2022 Oct 31];7(9):e156973–e156973. https://pubmed.ncbi.nlm.nih.gov/35316224/.
- Zamani N, Hassanian-Moghaddam H, Bayat AH, et al. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine. Toxicol Lett [Internet] 2015 [cited 2022 Oct 31];232(3):590–594. https://pubmed.ncbi.nlm.nih.gov/25510513/.
- Zamani N, Buckley NA, Hassanian-Moghaddam H. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Crit Care [Internet] 2020 [cited 2022 Oct 31];24(1):44–44. https://pubmed.ncbi.nlm.nih.gov/32033582/.
- Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med [Internet] 2018 [cited 2022 Oct 31];169(3):137–145. https://pubmed.ncbi.nlm.nih.gov/29913516/.
- Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med [Internet] 2014 [cited 2022 Oct 31];370(22):2063–2066. https://pubmed.ncbi.nlm.nih.gov/24758595/.
- Wightman RS, Perrone J, Scagos R, et al. Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis. J Med Toxicol 2020;17:10–5. doi:10.1007/s13181-020-00795-3
- Komatsu R, Singleton MD, Peperzak KA, et al. Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine. JA Clin Rep [Internet] 2022 [cited 2022 Dec 16];8(1):45–45. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209540/.
- Richards S, Torre L, Lawther B. Buprenorphine-related complications in elderly hospitalised patients: a case series. Anaesth Intensive Care [Internet] 2017 [cited 2022 Oct 31];45(2):256–261. https://pubmed.ncbi.nlm.nih.gov/28267949/.
- Moss LM, Algera MH, Dobbins R, et al. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLos One 2022;17:e0256752.
- Kunzler NM, Wightman RS, Nelson LS. Opioid withdrawal precipitated by long-acting antagonists. J Emerg Med [Internet] 2020 [cited 2022 Oct 31];58(2):245–253. https://pubmed.ncbi.nlm.nih.gov/32005608/.
- Quattlebaum THN, Kiyokawa M, Murata KA. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. Fam Pract [Internet] 2022 [cited 2022 Oct 31];39(2):292–294. https://pubmed.ncbi.nlm.nih.gov/34173647/.
- Oakley B, Wilson H, Hayes V, et al. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug Alcohol Rev [Internet] 2021 [cited 2022 Oct 31];40(4):567–571. https://pubmed.ncbi.nlm.nih.gov/33480051/.
- Phillips RH, Salzman M, Haroz R, et al. Elective naloxone-induced opioid withdrawal for rapid initiation of medication-assisted treatment of opioid use disorder. Ann Emerg Med 2019;74:430–2. doi:10.1016/j.annemergmed.2019.01.006
- Chhabra N, Aks SE. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine. Am J Emerg Med [Internet] 2020 [cited 2022 Oct 31];38(3):691.e3–691.e4. https://pubmed.ncbi.nlm.nih.gov/31753622/.
- Yokell MA, Zaller ND, Green TC, et al. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose. J Opioid Manag 2012;8:63. doi:10.5055/jom.2012.0098
- Carroll G, Solomon KT, Heil J, et al. Impact of administering buprenorphine to overdose survivors using emergency medical services. Ann Emerg Med [Internet] 2022;8(2):165–175. https://pubmed.ncbi.nlm.nih.gov/36192278/.
- Krotulski AJ, Chapman BP, Marks SJ, et al. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose. Clin Toxicol [Internet] 2022 [cited 2022 Oct 31];60(2):197–204. https://pubmed.ncbi.nlm.nih.gov/34278904/.
- Dahan A, van Lemmen M, Jansen S, et al. Buprenorphine: a treatment and cause of opioid-induced respiratory depression. Br J Anaesth [Internet] 2022 [cited 2022 Oct 31];128(3):402–404. https://pubmed.ncbi.nlm.nih.gov/34996591/.
- Abrahamsson T, Berge J, Öjehagen A, et al. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-a nation-wide register-based open cohort study. Drug Alcohol Depend [Internet] 2017 [cited 2022 Oct 31];174:58–64. https://pubmed.ncbi.nlm.nih.gov/28315808.
- Dupouy J, Palmaro A, Fatséas M, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Fam Med [Internet] 2017 [cited 2022 Oct 31];15(4):355–358. https://pubmed.ncbi.nlm.nih.gov/28694272/.
- Armoon B, SoleimanvandiAzar N, Rostami M, et al. Drug type and risk behaviors associated with non-fatal overdose among people who use drugs: a systematic review and meta-analysis. J Addict Dis [Internet] 2022 [cited 2022 Oct 31];40(1):114–125. https://pubmed.ncbi.nlm.nih.gov/34286664/.
- Yung L, Lee KC, Hsu C, et al. Patterns of naloxone use in hospitalized patients. Postgrad Med [Internet] 2017 [cited 2022 Oct 31];129(1):40–45. https://pubmed.ncbi.nlm.nih.gov/27858510/.
- Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLos Med [Internet] 2017 [cited 2022 Oct 31];14(10):e1002396–e1002396. https://pubmed.ncbi.nlm.nih.gov/28972983/.
- Savelloni J, Gunter H, Lee KC, et al. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res 2017;10:2635. doi:10.2147/JPR.S144963
- van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology [Internet] 2006 [cited 2022 Oct 31];105(1):51–57. https://pubmed.ncbi.nlm.nih.gov/16809994/.
- Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet [Internet] 2007 [cited 2022 Oct 31];46(11):965–980. https://pubmed.ncbi.nlm.nih.gov/17922561/.
- Krikorian A, Maldonado C, Pastrana T. Patient’s perspectives on the notion of a good death: a systematic review of the literature. J Pain Symptom Manage [Internet] 2020 [cited 2022 Dec 23];59(1):152–164. https://pubmed.ncbi.nlm.nih.gov/31404643/.
- Zale EL, Lange KL, Fields SA, et al. The relation between pain-related fear and disability: a meta-analysis. J Pain [Internet] 2013 [cited 2022 Dec 23];14:1019–1030. https://pubmed.ncbi.nlm.nih.gov/23850095/.
- Klint Å, Bondesson E, Rasmussen BH, et al. Dying with unrelieved pain—prescription of opioids is not enough. J Pain Symptom Manag 2019;58:784–91.e1. doi:10.1016/j.jpainsymman.2019.07.006
- Li X, Li N, Lu Y, et al. Knowledge of opioid-induced respiratory depression among Chinese health care professionals: a cross-sectional study. Asia-Pacific J Oncol Nurs [Internet] 2021 [cited 2022 Oct 31];9(1):55–60. https://pubmed.ncbi.nlm.nih.gov/35528797/.
- Gardiner C, Gott M, Ingleton C, et al. Attitudes of health care professionals to opioid prescribing in end-of-life care: a qualitative focus group study. J Pain Symptom Manage [Internet] 2012 [cited 2022 Dec 22];44(2):206–214. https://pubmed.ncbi.nlm.nih.gov/22672918/.
- Gerber K, Willmott L, White B, et al. Barriers to adequate pain and symptom relief at the end of life: a qualitative study capturing nurses’ perspectives. Collegian 2022;29:1–8. doi:10.1016/j.colegn.2021.02.008
- Morita T, Tsunoda J, Inoue S, et al. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage [Internet] 2001 [cited 2022 Dec 22];21(4):282–289. https://pubmed.ncbi.nlm.nih.gov/11312042/.
- Sathornviriyapong A, Nagaviroj K, Anothaisintawee T. The association between different opioid doses and the survival of advanced cancer patients receiving palliative care. BMC Palliat Care [Internet] 2016 [cited 2022 Dec 22];15(1):95–95. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117570/.
- Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol [Internet] 2003 [cited 2022 Dec 22];4(5):312–318. https://pubmed.ncbi.nlm.nih.gov/12732169/.
- Sutradhar R, Atzema C, Seow H, et al. Repeated assessments of symptom severity improve predictions for risk of death among patients with cancer. J Pain Symptom Manage [Internet] 2014 [cited 2022 Dec 22];48(6):1041–1049. https://pubmed.ncbi.nlm.nih.gov/24768594/.
- Lee SC, Klein-Schwartz W, Doyon S, et al. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug Alcohol Depend [Internet] 2014 [cited 2022 Oct 31];138:118–123. https://pubmed.ncbi.nlm.nih.gov/24629782/.